Stay updated on Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Sign up to get notified when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.

Latest updates to the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page
- Check2 days agoChange DetectedAdded Study Design and Study Status entries in the latest history versions; a previous entry dated 2026-03-05 was removed.SummaryDifference0.5%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedFooter now shows Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check24 days agoChange DetectedAdded a new Study Status entry to the record history and updated the record to revision v3.4.3 on 2026-03-05.SummaryDifference0.5%

- Check53 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-government-funding notice and the prior Revision: v3.4.1 from the history.SummaryDifference0.8%

- Check60 days agoChange DetectedAdded a site-wide notice about government funding and operating status, and updated the record history to revision 3.4.1 (replacing 3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check67 days agoChange DetectedAdded a 'Show glossary' option and color-coded change indicators (green for additions and red for deletions); updated the revision from v3.3.4 to v3.4.0 and removed the 'No FEAR Act data' entry.SummaryDifference1%

Stay in the know with updates to Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.